Benchmark Co. Keeps Their Buy Rating on Harvard Bioscience (HBIO)
Benchmark Co. analyst Bruce Jackson has maintained a Buy rating on Harvard Bioscience (HBIO) with a price target of $2.00. The consensus among analysts is a Moderate Buy, also with a $2.00 target. Jackson, who covers the Healthcare sector, has an average return of -11.2% and a 35.29% success rate on his stock recommendations.
In a report released today, Bruce Jackson from Benchmark Co. maintained a Buy rating on Harvard Bioscience, with a price target of $2.00.
Meet Your ETF AI Analyst
- Discover how TipRanks' ETF AI Analyst can help you make smarter investment decisions
- Explore ETFs TipRanks' users love and see what insights the ETF AI Analyst reveals about the ones you follow.
Jackson covers the Healthcare sector, focusing on stocks such as Belite Bio, Inc. ADR, Abbott Laboratories, and Exact Sciences. According to TipRanks, Jackson has an average return of -11.2% and a 35.29% success rate on recommended stocks.
Currently, the analyst consensus on Harvard Bioscience is a Moderate Buy with an average price target of $2.00.
